CPRX.OQ
Latest Trade
4.44USDChange
-0.03(-0.67%)Volume
350,091Today's Range
-
4.4652 Week Range
-
5.18As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 4.47 |
|---|---|
Open | 4.45 |
Volume | 350,091 |
3M AVG Volume | 35.64 |
Today's High | 4.46 |
Today's Low | 4.30 |
52 Week High | 5.18 |
52 Week Low | 2.88 |
Shares Out (MIL) | 103.82 |
Market Cap (MIL) | 460.98 |
Forward P/E | 12.28 |
Dividend (Yield %) | -- |
Catalyst Pharmaceuticals Announces $40 Mln Share Repurchase Program
Catalyst Pharmaceuticals Posts Q4 EPS Of $0.11
Catalyst Pharmaceuticals Announces Filing Of Patent Infringement Actions Against Jacobus Pharmaceuticals And Pantherrx
Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.
Industry
Biotechnology & Drugs
Contact Info
355 Alhambra Cir Ste 1250
CORAL GABLES, FL
33134-5038
United States
+1.305.5292522
https://catalystpharma.com/Executive Leadership
Patrick James McEnany
Chairman of the Board, President, Chief Executive Officer
Alicia Grande
Chief Financial Officer, Vice President, Treasurer
Steven R. Miller
Chief Operating Officer, Chief Scientific Officer
Brian D. Elsbernd
Chief Compliance Officer, Chief Legal Officer
Jeffrey Del Carmen
Chief Commercial Officer
Price To Earnings (TTM) | 6.30 |
|---|---|
Price To Sales (TTM) | 3.87 |
Price To Book (MRQ) | 2.72 |
Price To Cash Flow (TTM) | 6.14 |
Total Debt To Equity (MRQ) | 0.00 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | 58.15 |
Return on Equity (TTM) | 49.21 |
* DRUG SUPPLY REMAINS WELL-STOCKED WITH PATIENTS HAVING ACCESS TO UNINTERRUPTED SUPPLY OF FIRDAPSE (AMIFAMPRIDINE) 10MG
* CATALYST PHARMACEUTICALS CEO, ON IMPACT OF COVID-19, SAYS IMPLEMENTING VIRTUAL APPROACH TO GUARANTEE PATIENTS CONTINUAL ACCESS TO FIRDAPSE
* CATALYST PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR-END 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Catalyst Pharmaceuticals Inc, which has come under fire for the high price tag on its rare disease drug, on Wednesday sued the U.S. Food and Drug Administration to challenge the recent approval of a lower-cost rival drug.
Catalyst Pharmaceuticals Inc said on Wednesday it has filed a lawsuit against the U.S. Food and Drug Administration, challenging the recent approval of Jacobus Pharmaceutical Co's drug, Ruzurgi, for a rare neuromuscular disease.
U.S. Senator Bernie Sanders this week urged regulators to allow pharmacies and manufacturers to resume distributing unbranded, lower-cost versions of a drug used to treat a rare neuromuscular disorder, according to a letter provided by his office to Reuters.
Catalyst Pharmaceuticals Inc, rebuked by U.S. Senator Bernie Sanders for its high drug prices, on Thursday defended its $375,000 treatment for a rare disease, saying the price was in line with similar products in the industry.
Catalyst Pharmaceuticals Inc, targeted by U.S. Senator Bernie Sanders for high drug prices, said on Thursday that prices of its treatment for a rare neurological disorder were "in line" with similar products in the industry.
Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease, which had long been available to patients for free, will cost more than $300,000 per year including rebates to insurers and other discounts.
The U.S. Food and Drug Administration approved on Wednesday Catalyst Pharmaceuticals Inc's drug to treat a rare autoimmune disease.
The U.S. Food and Drug Administration approved on Wednesday Catalyst Pharmaceuticals Inc's drug to treat a rare autoimmune disease.
* CATALYST PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
* CATALYST PHARMACEUTICALS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 3 TRIAL OF FIRDAPSE® IN MUSK ANTIBODY POSITIVE MYASTHENIA GRAVIS Source text for Eikon: Further company coverage:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.